Press Release
29 September 2026 13:00:00 CEST

PILA PHARMA AB
Norra Vallgatan 72, 211 22 Malmö, Sweden
www.pilapharma.com.com

PILA PHARMA: FIRST CLINICAL SITE INITIATED AND ACTIVATED, ENROLLMENT COMMENCES FOR SAFETY PART 1 OF PP-CT04, A 12-WEEK CLINICAL TRIAL IN PEOPLE LIVING WITH OBESITY

29 September 2026, Malmö, Sweden: PILA PHARMA AB (publ) (FN STO: PILA), a clinical stage biotech company pioneering development of an oral TRPV1-antagonist as a potential first-in-class treatment for obesity and diabetes, today announces it has initiated the clinical trial site that will conduct the Part 1 (safety) of PP-CT04 and the site has been given permission to enroll participants.

The site initiation and activation is the final step before the clinical site can enroll participants in the trial. It ensures that the principal investigator and trial staff have been trained in the trial protocol, that the regulatory and ethics documentation is in place, and that the site's procedures and facilities meet the requirements of the trial and GCP regulations.

PP-CT04 is a two-part, randomised, double-blind, placebo-controlled, parallel-group, 12-week trial investigating the safety, tolerability, pharmacokinetics and efficacy of XEN-D0501 in obese participants.

The trial is designed to explore a within-subject dose titration approach to reach anticipated therapeutic plasma concentrations of XEN-D0501 not previously investigated.

Dose escalation will be carried out individually for each participant, beginning at 4 mg BID and increasing stepwise up to a maximum of 16 mg BID. Each dose level will be administered for 1 week, resulting in a maximum dose escalation period of 4 weeks. Once the highest tolerable dose has been reached and confirmed to be tolerable, the participant will continue treatment at that dose for an 8-week maintenance period.

PILA PHARMA AB
Norra Vallgatan 72, 211 22 Malmö, Sweden
www.pilapharma.com.com

PP-CT04 is divided into two parts with the same overall design, but Part 1, as a pilot safety cohort with 8 participants, entails more intense safety monitoring. It is enrolment for this Part 1 that will begin now in collaboration with **Clinical Trial Consultants AB**.

Part 2 may start once all participants in Part 1 have been dosed for at least 5 weeks and once a favourable recommendation has been given by the internal safety review committee.

Chief Scientific Officer and Founder, Dorte X. Gram comments:
"The initiation and activation of the clinical site are important milestones as it concludes weeks of formal preparation following the regulatory approval of the trial, whereby numerous documents for compliant trial execution are completed. The site initiation visit itself allows for the Sponsor, PILA, to meet the actual trial staff, share our story, and our vision for developing a TRPV1 antagonist as treatment of obesity and co-morbidities, a simple, accessible tablet solution with a differentiated safety profile, that could be a good fit to current market needs."

For more information:

Gustav H. Gram, CEO
ghg@pilapharma.com

PILA PHARMA's share ticker PILA is subject to trade on Nasdaq First North Growth Market, Sweden with Aqurat Fondkommission AB as Certified Adviser. Contact: M: **ca@aqurat.se** - T: +46 (0)8 684 05 800

Press Release
29 September 2026 13:00:00 CEST

PILA PHARMA AB
Norra Vallgatan 72, 211 22 Malmö, Sweden
www.pilapharma.com.com

About PILA PHARMA AB (Publ)

PILA PHARMA AB is a Swedish clinical stage biotech company based in Malmö, Sweden. The aim of the company is to develop TRPV1 antagonists as a novel treatment of obesity and diabetes. The Company owns a TRPV1 asset with data and chemical entities including the clinical development candidate XEN-D0501. In August 2026, the Company had a clinical trial application approved for a new 12-week clinical trial in people living with obesity. The Company was moreover holds an orphan drug designation ("ODD") for XEN-D0501 as a treatment for the painful rare disease erythromelalgia.